Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 128084, 3 pages

New Insights into Malignant B-Cell Disorders

1Hematology Section of First Department of Propaedeutic Internal Medicine, University of Athens Medical School, Laikon General Hospital of Athens, Athens, Greece
2The Japanese Society of Myeloma, Hematology Section of Internal Medicine, Tokai Chuo Hospital, Kakamigahara, Japan
3Department of Haematology, Athens Medical Center, Psychikon Branch, Athens, Greece

Received 8 December 2014; Accepted 8 December 2014

Copyright © 2015 Marie-Christine Kyrtsonis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Swerdlow, E. Campo, and N. E. Harris, Eds., WHO Classification Of Tumours Of Haematipoetic And Lymphoid Tissues, IARC Press, Lyon, France, 2008.
  2. B. Barlogie, A. Mitchell, F. van Rhee, J. Epstein, G. J. Morgan, and J. Crowley, “Curing myeloma at last: defining criteria and providing the evidence,” Blood, vol. 124, no. 20, pp. 3043–3051, 2014. View at Publisher · View at Google Scholar
  3. H. Ludwig, P. Sonneveld, F. Davies et al., “European perspective on multiple myeloma treatment strategies in 2014,” Oncologist, vol. 19, no. 8, pp. 829–844, 2014. View at Google Scholar
  4. E. M. Ocio, P. G. Richardson, S. V. Rajkumar et al., “New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG),” Leukemia, vol. 28, no. 3, pp. 525–542, 2014. View at Publisher · View at Google Scholar
  5. J. C. Byrd, R. R. Furman, S. E. Coutre et al., “Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia,” The New England Journal of Medicine, vol. 369, no. 1, pp. 32–42, 2013. View at Publisher · View at Google Scholar
  6. J. A. Kanakry and R. F. Ambinder, “Old variables, new value: a refined IPI for DLBCL,” Blood, vol. 123, no. 6, pp. 800–801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Martelli, A. J. Ferreri, C. Agostinelli, A. Di Rocco, M. Pfreundschuh, and S. A. Pileri, “Diffuse large B-cell lymphoma,” Critical Reviews in Oncology/Hematology, vol. 87, no. 2, pp. 146–171, 2013. View at Google Scholar
  8. A. Klepfish, B. Zuckermann, and A. Schattner, “Primary Effusion Lymphoma (PEL) in the absence of HIV infection—clinical presentation and management,” QJM. In press.
  9. X. Yiakoumis, G. A. Pangalis, M. C. Kyrtsonis et al., “Primary effusion lymphoma in two HIV-negative patients successfully treated with pleurodesis as first-line therapy,” Anticancer Research, vol. 30, no. 1, pp. 271–276, 2010. View at Google Scholar · View at Scopus
  10. G. A. Pangalis, M. C. Kyrtsonis, F. N. Kontopidou et al., “Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders,” Clinical Lymphoma, vol. 5, no. 4, pp. 235–240, 2005. View at Google Scholar
  11. O. Landgren, R. A. Kyle, R. M. Pfeiffer et al., “Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study,” Blood, vol. 113, no. 22, pp. 5412–5417, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Carbone and A. Santoro, “How I treat: diagnosing and managing “in situ” lymphoma,” Blood, vol. 117, no. 15, pp. 3954–3960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. A. Parikh, N. E. Kay, and T. D. Shanafelt, “Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling,” Clinical Advances in Hematology and Oncology, vol. 11, no. 11, pp. 720–729, 2013. View at Google Scholar · View at Scopus
  14. Y. K. Shim, J. M. Rachel, P. Ghia et al., “Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding,” Blood, vol. 123, no. 9, pp. 1319–1326, 2014. View at Publisher · View at Google Scholar